Drugs / COM902
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04354246 | Mar 2020 → Apr 2026 | colon carcinoma, head and neck squamous cell carcinoma, lung cancer, ovarian cancer +1 | Compugen Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COM902 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04354246 ↗ |
| Action | Inhibit | “COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies” NCT04354246 ↗ |
| Route | Intravenous | “COM902 monotherapy administered IV every 3 weeks in sequential dose escalation doses in cohorts of subjects.” NCT04354246 ↗ |